<DOC>
	<DOCNO>NCT00137930</DOCNO>
	<brief_summary>Rotavirus ( RV ) important cause acute gastroenteritis ( GE ) require hospitalization infant young child develop develop country frequent cause death child less 5 year age ( estimate nearly 500,000 annual death worldwide ) . GlaxoSmithKline ( GSK ) Biologicals develop vaccine human rotavirus gastroenteritis . A new formulation vaccine , alternative buffer , develop . This study conduct evaluate new formulation compare exist formulation HRV vaccine .</brief_summary>
	<brief_title>Study Immunogenicity &amp; Safety 2 Different Formulations Human Rotavirus ( HRV ) Vaccine Prophylaxis Rotavirus Gastroenteritis</brief_title>
	<detailed_description>The study consist four group child recruit different center Finland . One group child receive exist formulation HRV vaccine one group receive new formulation HRV vaccine . The two group receive placebo exist formulation new formulation base allocation . The vaccine placebo administer start 6 - 12 week age accord 0 , 1 month schedule . Routine childhood vaccination allow accord local practice , least 14 day apart dose study vaccine . The duration study approximately 2 month per child .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects parents/guardians investigator believe comply requirement protocol enrol study . Males female , include , 6 12 week ( 42 90 day ) age time first vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Born gestation period 36 42 week inclusive . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Planned administration vaccine ( include routine paediatric vaccine ) foresee study protocol period start 14 day dose study vaccine ( ) end 14 day . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . ( For corticosteroid , mean prednisone , equivalent , 0.5 mg/kg/day . Inhaled topical steroid allow . ) Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation gastrointestinal tract serious medical condition , determine investigator . History allergic disease reaction likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . Major congenital defect serious chronic illness . Acute disease time enrolment . ( Acute disease define presence moderate severe illness without fever , i.e . temperature &gt; = 37.5°C measure axillary thermometer &gt; = 38.0°C measured rectal thermometer . ) Temperature great equal cutoff warrant deferral vaccination pending recovery subject . Gastroenteritis ( GE ) within 7 day precede study vaccine administration ( warrant deferral vaccination ) . Household contact immunosuppressed individual pregnant woman . Administration immunoglobulins and/or blood product since birth plan administration study period . Previous confirm occurrence RV GE . History neurological disorder seizure .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prophylaxis rotavirus gastroenteritis</keyword>
</DOC>